PE20120322A1 - Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante - Google Patents
Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionanteInfo
- Publication number
- PE20120322A1 PE20120322A1 PE2011002086A PE2011002086A PE20120322A1 PE 20120322 A1 PE20120322 A1 PE 20120322A1 PE 2011002086 A PE2011002086 A PE 2011002086A PE 2011002086 A PE2011002086 A PE 2011002086A PE 20120322 A1 PE20120322 A1 PE 20120322A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- weight
- pharmaceutical composition
- amount
- emulsing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- LLGDPTDZOVKFDU-XUHJSTDZSA-N faldaprevir Chemical compound N([C@H](C(=O)N1[C@@H](C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1N=C(NC(=O)C(C)C)SC=1)Br)OC)C(=O)N[C@]1([C@@H](C1)C=C)C(O)=O)C(C)(C)C)C(=O)OC1CCCC1 LLGDPTDZOVKFDU-XUHJSTDZSA-N 0.000 title 1
- 229960003777 faldaprevir Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- -1 PROPYLENE GLYCOL FATTY ACIDS Chemical class 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 101800001098 Serine protease NS3 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 235000019149 tocopherols Nutrition 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA LIQUIDA QUE CONTIENE: A) UN COMPUESTO INHIBIDOR DE LA SERINA PROTEASA NS3 DEL VIRUS DE LA HEPATITIS C DE FORMULA (1) EN UNA CANTIDAD DE 1 A 50% EN PESO DE LA COMPOSICION; B) UNO O MAS LIPIDOS TAL COMO ACIDOS GRASOS, TRIGLICERIDOS, ESTERES DE ACIDOS GRASOS DE PROPILENGLICOL, ENTRE OTROS, EN UNA CANTIDAD DE 20 A 70% EN PESO DE LA COMPOSICION; C) UNO O MAS TENSIOACTIVOS HIDROFILOS TAL COMO ACEITES VEGETALES POLIETOXILADOS, TOCOFEROLES POLIETOXILADOS, SALES BILIARES, ENTRE OTROS, EN UNA CATIDAD DE HASTA 70% EN PESO DE LA COMPOSICION; Y D) UN DISOLVENTE HIDROFILO TAL COMO PROPILENGLICOL, POLIETILENGLICOL, GLICEROL, ETANOL, ENTRE OTROS, EN UNA CANTIDAD DE HASTA 30% EN PESO DE LA COMPOSICION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE INFECCION POR VHC
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22350709P | 2009-07-07 | 2009-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120322A1 true PE20120322A1 (es) | 2012-04-14 |
Family
ID=43245003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011002086A PE20120322A1 (es) | 2009-07-07 | 2010-07-01 | Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9034831B2 (es) |
| EP (1) | EP2451438B8 (es) |
| JP (1) | JP5607736B2 (es) |
| KR (1) | KR101685941B1 (es) |
| CN (1) | CN102470103B (es) |
| AP (1) | AP2011005979A0 (es) |
| AR (1) | AR077393A1 (es) |
| AU (1) | AU2010270783B2 (es) |
| BR (1) | BR112012000287B8 (es) |
| CA (1) | CA2767692C (es) |
| CL (1) | CL2012000054A1 (es) |
| CO (1) | CO6480980A2 (es) |
| DK (1) | DK2451438T3 (es) |
| EA (1) | EA023433B1 (es) |
| EC (1) | ECSP12011624A (es) |
| ES (1) | ES2464367T3 (es) |
| GE (1) | GEP20146016B (es) |
| HR (1) | HRP20140445T1 (es) |
| IL (1) | IL216098A (es) |
| MA (1) | MA33491B1 (es) |
| ME (1) | ME01718B (es) |
| MX (1) | MX2011013824A (es) |
| MY (1) | MY154683A (es) |
| NZ (1) | NZ596928A (es) |
| PE (1) | PE20120322A1 (es) |
| PL (1) | PL2451438T3 (es) |
| PT (1) | PT2451438E (es) |
| RS (1) | RS53209B (es) |
| SG (1) | SG177569A1 (es) |
| SI (1) | SI2451438T1 (es) |
| TN (1) | TN2012000009A1 (es) |
| TW (1) | TWI490216B (es) |
| UA (1) | UA104195C2 (es) |
| UY (1) | UY32760A (es) |
| WO (1) | WO2011005646A2 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY152824A (en) * | 2008-09-17 | 2014-11-28 | Boehringer Ingelheim Int | Combination of hcv ns3 protease inhibitor with interferon and ribavirin. |
| SG177569A1 (en) | 2009-07-07 | 2012-03-29 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
| AU2010313497B2 (en) | 2009-10-30 | 2013-08-01 | Boehringer Ingelheim International Gmbh | Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin |
| US20120135949A1 (en) | 2010-09-30 | 2012-05-31 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AP2014007760A0 (en) * | 2012-01-12 | 2014-07-31 | Boehringer Ingelheim Int | Stabilized pharmaceutical formulations of a potentHCV inhibitor |
| JP2015509980A (ja) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法 |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| BR112015007879A2 (pt) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | inibidores do vírus da hepatite c |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| US9732076B2 (en) * | 2013-03-15 | 2017-08-15 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of HCV inhibitor in the amorphous state |
| EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| CN114651010A (zh) | 2019-04-24 | 2022-06-21 | 赛诺菲生物技术公司 | 类风湿性关节炎的诊断和治疗方法 |
| EP3980459A1 (en) | 2019-06-04 | 2022-04-13 | Sanofi Biotechnology | Compositions and methods for treating pain in subj ects with rheumatoid arthritis |
| PH12021552872A1 (en) | 2020-04-05 | 2022-03-21 | Pfizer | Compounds and methods for the treatment of covid-19 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE445174B (sv) | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
| US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| IL102236A0 (en) | 1991-06-27 | 1993-01-14 | Ltt Inst Co Ltd | Topical preparations containing cyclosporin |
| US5329976A (en) | 1991-12-09 | 1994-07-19 | Habley Medical Technology Corporation | Syringe-filling and medication mixing dispenser |
| GB9208712D0 (en) | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
| SI1033128T2 (sl) | 1993-09-28 | 2012-02-29 | Scherer Gmbh R P | Izdelava mehke Ĺľelatinaste kapsule |
| EP0825849A1 (en) | 1995-05-19 | 1998-03-04 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
| US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| DK0999826T3 (da) * | 1997-07-29 | 2004-07-26 | Upjohn Co | Selv-emulgerende formulering til lipofile forbindelser |
| WO1999006044A1 (en) | 1997-07-29 | 1999-02-11 | Pharmacia & Upjohn Company | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
| DK0999838T3 (da) | 1997-07-29 | 2002-07-08 | Upjohn Co | Selv-emulgerende formulering for lipofile forbindelser |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6652880B1 (en) | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| CA2466851C (en) | 2001-11-26 | 2012-09-11 | Supergen, Inc. | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| CZ294371B6 (cs) | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| US20040033959A1 (en) * | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| UY28240A1 (es) | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| AU2004231538A1 (en) | 2003-04-02 | 2004-11-04 | Boehringer Ingelheim International, Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| PE20050204A1 (es) * | 2003-05-21 | 2005-05-04 | Boehringer Ingelheim Int | Compuestos inhibidores de la hepatitis c |
| MXPA06003141A (es) * | 2003-09-22 | 2006-06-05 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c. |
| KR20070009623A (ko) * | 2004-03-15 | 2007-01-18 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃ형 간염 바이러스 감염의 치료에 적합한 매크로사이클릭디펩타이드의 제조방법 |
| GEP20104926B (en) | 2004-03-30 | 2010-03-25 | Intermune Inc | Macrocyclic compounds as inhibitors of viral replication |
| CA2568008C (en) | 2004-05-25 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic hcv protease inhibitors |
| WO2006130552A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| RU2490272C2 (ru) | 2008-02-04 | 2013-08-20 | Айденикс Фармасьютикалз, Инк. | Макроциклические ингибиторы серинпротеазы |
| EP2331538B1 (en) | 2008-09-16 | 2014-04-16 | Boehringer Ingelheim International GmbH | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor |
| HRP20140097T1 (hr) | 2008-11-21 | 2014-03-14 | Boehringer Ingelheim International Gmbh | Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu |
| SG177569A1 (en) | 2009-07-07 | 2012-03-29 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
-
2010
- 2010-07-01 SG SG2012001368A patent/SG177569A1/en unknown
- 2010-07-01 MY MYPI2012000028A patent/MY154683A/en unknown
- 2010-07-01 BR BR112012000287A patent/BR112012000287B8/pt not_active IP Right Cessation
- 2010-07-01 RS RS20140116A patent/RS53209B/sr unknown
- 2010-07-01 PL PL10731685T patent/PL2451438T3/pl unknown
- 2010-07-01 SI SI201030565T patent/SI2451438T1/sl unknown
- 2010-07-01 PT PT107316853T patent/PT2451438E/pt unknown
- 2010-07-01 GE GEAP201012562A patent/GEP20146016B/en unknown
- 2010-07-01 NZ NZ596928A patent/NZ596928A/xx not_active IP Right Cessation
- 2010-07-01 MA MA34511A patent/MA33491B1/fr unknown
- 2010-07-01 AU AU2010270783A patent/AU2010270783B2/en not_active Ceased
- 2010-07-01 PE PE2011002086A patent/PE20120322A1/es active IP Right Grant
- 2010-07-01 JP JP2012519597A patent/JP5607736B2/ja not_active Expired - Fee Related
- 2010-07-01 ME MEP-2014-23A patent/ME01718B/me unknown
- 2010-07-01 CN CN201080030433.1A patent/CN102470103B/zh not_active Expired - Fee Related
- 2010-07-01 WO PCT/US2010/040734 patent/WO2011005646A2/en not_active Ceased
- 2010-07-01 EA EA201200096A patent/EA023433B1/ru not_active IP Right Cessation
- 2010-07-01 EP EP10731685.3A patent/EP2451438B8/en active Active
- 2010-07-01 HR HRP20140445AT patent/HRP20140445T1/hr unknown
- 2010-07-01 DK DK10731685.3T patent/DK2451438T3/da active
- 2010-07-01 UA UAA201201066A patent/UA104195C2/ru unknown
- 2010-07-01 KR KR1020127000354A patent/KR101685941B1/ko not_active Expired - Fee Related
- 2010-07-01 ES ES10731685.3T patent/ES2464367T3/es active Active
- 2010-07-01 CA CA2767692A patent/CA2767692C/en not_active Expired - Fee Related
- 2010-07-01 AP AP2011005979A patent/AP2011005979A0/xx unknown
- 2010-07-01 MX MX2011013824A patent/MX2011013824A/es active IP Right Grant
- 2010-07-05 UY UY0001032760A patent/UY32760A/es not_active Application Discontinuation
- 2010-07-06 TW TW099122196A patent/TWI490216B/zh not_active IP Right Cessation
- 2010-07-06 AR ARP100102427A patent/AR077393A1/es not_active Application Discontinuation
- 2010-07-06 US US12/830,771 patent/US9034831B2/en active Active
-
2011
- 2011-11-02 IL IL216098A patent/IL216098A/en active IP Right Grant
- 2011-12-29 CO CO11181070A patent/CO6480980A2/es not_active Application Discontinuation
-
2012
- 2012-01-05 TN TNP2012000009A patent/TN2012000009A1/en unknown
- 2012-01-06 CL CL2012000054A patent/CL2012000054A1/es unknown
- 2012-01-26 EC EC2012011624A patent/ECSP12011624A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120322A1 (es) | Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante | |
| GT201300077AA (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas (solicitud de patente fraccionaria de la solicitud no. a-2013-00077) | |
| RU2018133283A (ru) | Сложные эфиры для лечения офтальмологических воспалительных заболеваний | |
| MX2012014785A (es) | Compuestos moduladores de inmunosupresion. | |
| MX2009009997A (es) | Preparacion de la capsula de tamibarotene. | |
| CL2008003384A1 (es) | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
| CO6220926A2 (es) | Formulacion farmaceutica topica para la aplicacion de un farmaco antiinflamatorio no esferoidal (nsaid) | |
| PE20141056A1 (es) | Metodos para el tratamiento de vhc | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| AR074391A1 (es) | Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral | |
| AR082443A1 (es) | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa | |
| EP2638903A4 (en) | SUPPRESSOR FOR INCREASING THE BLOOD SUGAR MIRROR | |
| GT200600400A (es) | Formulaciones herbicidas liquidas de sulfonilurea | |
| PE20121359A1 (es) | Composicion farmaceutica que comprende oligopeptidos | |
| WO2010115002A3 (en) | Use of fatty acid mixtures as surfactants in pest control compositions | |
| PE20080062A1 (es) | Procedimiento de tratamiento de depositos de almacenamiento contaminados por micotoxinas | |
| AR056465A1 (es) | Composiciones que contienen derivados de taxano | |
| BR112014002594A2 (pt) | uso de diésteres de isossorbida como espessantes | |
| CO6400183A2 (es) | Formas de dosificación oral de bendamustina | |
| MX2015011074A (es) | Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma. | |
| AR078194A1 (es) | Composicion antiperspirante / desodorante | |
| PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
| CA2798180A1 (en) | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same | |
| AR040859A1 (es) | Composiciones farmaceuticas que comprenden una ascomicina | |
| PE20061077A1 (es) | Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |